Small pieces of nucleic acid, known as siRNAs (short obtrusive RNAs), can turn off the reproduction of nailed down proteins, a capital that makes them one of the more promising new classes of anticancer drugs in development. Indeed, at least two siRNA-based anticancer therapies, both delivered to tumors in nanoparticles, have begun human clinical trials. Now, three new reports focus the progress that researchers are making in third world country broadly applicable, nanoparticle-enabled siRNA anticancer therapeutics.

More: - Brought to my attention by